Fig. 1 · Structure

Documents & Downloads

FIIN-2

Cat. No. A12357 CAS 1633044-56-0

FGFR Inhibitor

FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 3.1, 4.3, 27, and 45 nM, respectively.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
FGFR1 3.09 nM
FGFR2 4.3 nM
FGFR3 27 nM
FGFR4 45.3 nM

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 EC50 1 nM Antiproliferative activity against mouse BaF3 cells harboring wild-type FGFR1 assessed as reduction in cell proliferation measured after 72 hrs by MTS assay [PMID: 34962782]
BaF3 EC50 1 nM Antiproliferative activity against mouse BaF3 cells harboring wild-type FGFR2 assessed as reduction in cell proliferation measured after 72 hrs by MTS assay [PMID: 34962782]
BaF3 EC50 1 nM Antiproliferative activity against mouse BaF3 cells harboring wild-type FGFR3 assessed as reduction in cell proliferation measured after 72 hrs by MTS assay [PMID: 34962782]
BaF3 EC50 1 nM Antiproliferative activity against mouse BaF3 cells harboring wild-type FGFR4 assessed as reduction in cell proliferation measured after 72 hrs by MTS assay [PMID: 34962782]
BaF3 EC50 58 nM Antiproliferative activity against mouse BaF3 cells harboring FGFR2 V564M mutant assessed as reduction in cell proliferation measured after 72 hrs by MTS assay [PMID: 34962782]

FIIN-2 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of FIIN-2 from 3 published references. In vitro models include FGFR4KV550L; chicken SRC.

FIIN-2 In Vitro Studies

The FGFR4KV550L and FGFR4KV550E studies assessed substrate phosphorylation following FIIN-2 treatment. Both reported effective inhibition of substrate phosphorylation by all mutants, including the V550L gate-keeper mutant. In a chicken SRC assay, FIIN-2 was moderately potent against SRC, with an IC50 of 330 nM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibition of Mutant Substrate Phosphorylation

Cell-based study · FGFR4KV550L [1]

In the FGFR4KV550L model, FIIN-2 effectively inhibited substrate phosphorylation by all mutants, including the V550L gate-keeper mutant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
substrate phosphorylation activitiesReported result FIIN-2 effectively inhibited the substrate phosphorylation ability of all mutants including the V550L gate-keeper mutant[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: FIIN-2

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S20); Methods > Peptide Substrate Phosphorylation Assay by Native Gel and MALDI-TOF Mass Spectrometry (S81); Figure 3 legend (S104)

substrate phosphorylation activities: substrate phosphorylation activities — Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S20); Figure 3 legend (S104)

Activity Against Chicken SRC

Cell-based study · chicken SRC (residues 251−533) [2]

FIIN-2 was incubated with chicken SRC and was moderately potent against SRC, with an IC50 of 330 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IC50 valuesIC50 330 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.01 nM to 25 μM
Exposure duration
for half an hour at room temperature
Method
incubated with kinases
Vehicle
4% DMSO
Reported limits
Not stated in the sentences used: control.
Methods and source locations

Compound reported in the paper: FIIN-2

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibitory potency of FIIN-2, TAS-120 and PRN1371 against FGFRs and SFKs (S15); Methods > Protein expression and purification (S69); Methods > Kinase inhibition assay (S90, S91, S93, S94, S96, S97)

IC50 values: IC50 values — Results > Inhibitory potency of FIIN-2, TAS-120 and PRN1371 against FGFRs and SFKs (S15); Methods > Kinase inhibition assay (S97)

Peptide Substrate Phosphorylation in a Mutant Model

Cell-based study · FGFR4KV550E [1]

In the FGFR4KV550E model, peptide substrate phosphorylation was assessed following FIIN-2 treatment. The reported result was effective inhibition of substrate phosphorylation by all mutants, including the V550L gate-keeper mutant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Peptide substrate phosphorylation activitiesReported result FIIN-2 effectively inhibited the substrate phosphorylation ability of all mutants including the V550L gate-keeper mutant[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: FIIN-2

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S17, S20); Methods > Peptide Substrate Phosphorylation Assay by Native Gel and MALDI-TOF Mass Spectrometry (S81)

Peptide substrate phosphorylation activities: Peptide substrate phosphorylation activities — Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S20); Methods > Peptide Substrate Phosphorylation Assay by Native Gel and MALDI-TOF Mass Spectrometry (S81)

FIIN-2 In Vivo Studies

FIIN-2 was administered by intraperitoneal injection to female BALB/c nude mice bearing A549/DDP-derived xenografts. Tumour volume and weight were significantly reduced compared with control or CQ-treated mice. [3]

Tumour reduction in a nude mouse xenograft model

Animal study · Five-week-old female nude mice (BALB/c); nude mouse xenograft model derived from A549/DDP cells; n = 5 [3]

In female BALB/c nude mice bearing A549/DDP-derived xenografts, FIIN-2 was administered by intraperitoneal injection. Tumour volume and weight were significantly reduced compared with control or CQ-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumour volumeReported result FIIN-2 (20 mg/kg, bid.) via intraperitoneal injection for 28 consecutive days: the volume and weight of the tumours from FIIN-2-treated mice were significantly reduced compared to control or CQ-treated mice.[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
bid.; 28 consecutive days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FIIN-2 20 mg/kgvehicle control (100 μL saline solution, qd.)FIIN-2 (20 mg/kg, bid.) via intraperitoneal injection for 28 consecutive days: the volume and weight of the tumours from FIIN-2-treated mice were significantly reduced compared to control or CQ-treated mice.[3]
FIIN-2 20 mg/kg
Model: Five-week-old female nude mice (BALB/c); nude mouse xenograft model derived from A549/DDP cells; n = 5
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: FIIN-2

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Xenograft tumour model experiment (S81, S82); Results > Combined treatment with autophagy inhibitors augmented the anti-LUAD effect of FIIN-2 in vivo (S166); Fig. 6 legend (S189, S190, S191, S193)

tumour volume: tumour volume; comparator: vehicle control (100 μL saline solution, qd.) — Results > Combined treatment with autophagy inhibitors augmented the anti-LUAD effect of FIIN-2 in vivo (S166); Fig. 6 legend (S190, S191)

FIIN-2 20 mg/kg · Results > Combined treatment with autophagy inhibitors augmented the anti-LUAD effect of FIIN-2 in vivo (S166); Fig. 6 legend (S190)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1633044-56-0
Applications FGFR Inhibitor
Formula C35H38N8O4
Molecular Weight 634.73
SMILES
O=C1N(C2=CC(OC)=CC(OC)=C2)CC(C=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=N5)=C5N1CC6=CC=C(NC(C=C)=O)C=C6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 62 mg/mL (97.67 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FIIN-2 Research References

  1. [1] Huang Z, Tan L, Wang H, et al. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. ACS Chem Biol (2015). PMID: 25317566 DOI: 10.1021/cb500674s Source material
  2. [2] Qu L, Chen X, Wei H, et al. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Commun Chem (2022). PMID: 36697561 DOI: 10.1038/s42004-021-00623-x Source material
  3. [3] Jia X, Xin M, Xu J, et al. Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma. Cell Death Dis (2022). PMID: 36042213 DOI: 10.1038/s41419-022-05201-0 Source material

Added to your cart

View Cart Checkout
Loading...